Catalog No.
Product Name
Application
Product Information
Citations
-
DNA topoisomerase I/II inhibitor
Intoplicine is a DNA topoisomerase I and II inhibitor. -
telomerase inhibitor
TMPyP4 tosylate (TMP 1363) is a telomerase inhibitor with antitumor effects in osteosarcoma cell lines. -
DNA alkylator
DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer. -
PARP1/2 inhibitor
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.- Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
-
PARP-2 inhibitor
PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC50 of 11.5 nM. -
antibacterial candidate for clinical trials
Zabofloxacin (DW-224a Free base) is a novel fluoronaphthyridone quinolone with a 7-pyrrolidone substituent that is considered a potent antibacterial candidate for clinical trials. -
pan HDAC inhibitor
Tefinostat (CHR-2845) is a monocyte/macrophage-targeted pan HDAC inhibitor, cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Anti-monocytoid lineage leukaemias activity. -
HDAC inhibitor
Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC50 of 15.7 nM. -
PARG inhibitor
PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with an IC50 of 26 nM, and a KD of 1.45 nM. - Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.
-
BRCA1 inhibitor
BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively. -
PPI inhibitor
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions. - 2-(Methylamino)-1H-purin-6(7H)-one (N2-Methylguanine) is a modified nucleoside. 2-(Methylamino)-1H-purin-6(7H)-one is an endogenous methylated nucleoside found in human fluids.
- 6-Amino-5-nitropyridin-2-one is a pyridine base and used as a nucleobase of hachimoji DNA, in which it pairs with 5-aza-7-deazaguanine.
- Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (HCV) replication.
- Nucleoside-Analog-1 is a 4??-Azidocytidine analogue against Hepatitis C virus replication.
-
eIF4G1 inhibitor
SBI-0640756 (SBI-756) is a water soluble inhibitor of eIF4G1 and disrupts the eIF4F complex. -
PNP inhibitor
Forodesine(BCX-1777 freebase; Immucillin-H) is an orally bioavailable PNP inhibitor with picomolar potency; induces apoptosis, mainly in T cells. -
PNP inhibitor
Forodesine hydrochloride (BCX-1777) is a highly potent and specific purine nucleoside phosphorylase (PNP) inhibitor. -
RdRp inhibitor
Galidesivir hydrochloride (BCX 4430 hydrochloride) is a viral RNA-dependent RNA polymerase (RdRp) inhibitor; demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. -
HDAC inhibitor
CG-200745 is a potent HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. -
alkylating agent
Satraplatin is an alkylating agent, with potent antitumor effect. -
HDAC1 inhibitor
Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
